Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study
MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (PK/PD) data in baboons suggest that the increased binding to FcRn reduces the nonspecific elimination rate (Kel) of MTRX1011A...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2011-02, Vol.89 (2), p.283-290 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 290 |
|---|---|
| container_issue | 2 |
| container_start_page | 283 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 89 |
| creator | Zheng, Y Scheerens, H Davis, JC Deng, R Fischer, SK Woods, C Fielder, PJ Stefanich, EG |
| description | MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (PK/PD) data in baboons suggest that the increased binding to FcRn reduces the nonspecific elimination rate (Kel) of MTRX1011A by ~50% but does not affect its PK–PD relationship. The human PK/PD data of MTRX1011A from a phase I study in patients with rheumatoid arthritis (RA) were compared with those previously reported for TRX1, its predecessor antibody, using population PK–PD modeling. The results suggest a comparable PK–PD relationship and no significant difference between the Kel values of the two antibodies. However, the results may have been confounded by the differences in the clinical populations in which the two antibodies were studied and the presence of preexisting immunoglobulin M (IgM) antibodies in the RA sera that recognize N434H in MTRX1011A. This study highlights the challenges in translating from animal studies to human application the effects of FcRn‐directed mutations on the PK of monoclonal antibodies.
Clinical Pharmacology & Therapeutics (2011) 89 2, 283–290. doi:10.1038/clpt.2010.311 |
| doi_str_mv | 10.1038/clpt.2010.311 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_846902705</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>846902705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4641-7010c9d461e3a8910e5783d08d562b3d0cacacc9710ecd527823d1606a4adae43</originalsourceid><addsrcrecordid>eNp9kEtvEzEUhS1ERdPCki0yi6qrKX7My8tqIFApFREEttaN7QiDxw72jKr8Bv40HiYNu8oL-5773WP7IPSakhtKePtOuf1ww0guOaXP0IJWnBV1xavnaEEIEYVgvD5HFyn9zGUp2vYFOmeUCsqbdoH-bCL45GCwwYPD6x8Qe1Dhl_VmsCph8Pok6oOHfhLDLut4qb744jtEC37At36wRfe-xPfBB-X-mU3aNk_hZQw9XkejnPVW5c590MbhIUzWyeA7_HUY9eElOtuBS-bVcb9E35YfNt2nYvX54113uypUWZe0aPJnldBlTQ2HVlBiqqblmrS6qtk2HxTkpUSTO0pXrGkZ17QmNZSgwZT8El3PvvsYfo8mDbK3SRnnwJswJtmWtSCsIVUmi5lUMaQUzU7uo-0hHiQlcopfTvHLKX6Z48_8m6PzuO2NPtGPeWfg6ghAykHscvjKpv8cF5xRMnFi5h6sM4enb5XdetOt1pupnh_xdp71MIzRnIanoUfmL-FSq2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>846902705</pqid></control><display><type>article</type><title>Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Zheng, Y ; Scheerens, H ; Davis, JC ; Deng, R ; Fischer, SK ; Woods, C ; Fielder, PJ ; Stefanich, EG</creator><creatorcontrib>Zheng, Y ; Scheerens, H ; Davis, JC ; Deng, R ; Fischer, SK ; Woods, C ; Fielder, PJ ; Stefanich, EG</creatorcontrib><description>MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (PK/PD) data in baboons suggest that the increased binding to FcRn reduces the nonspecific elimination rate (Kel) of MTRX1011A by ~50% but does not affect its PK–PD relationship. The human PK/PD data of MTRX1011A from a phase I study in patients with rheumatoid arthritis (RA) were compared with those previously reported for TRX1, its predecessor antibody, using population PK–PD modeling. The results suggest a comparable PK–PD relationship and no significant difference between the Kel values of the two antibodies. However, the results may have been confounded by the differences in the clinical populations in which the two antibodies were studied and the presence of preexisting immunoglobulin M (IgM) antibodies in the RA sera that recognize N434H in MTRX1011A. This study highlights the challenges in translating from animal studies to human application the effects of FcRn‐directed mutations on the PK of monoclonal antibodies.
Clinical Pharmacology & Therapeutics (2011) 89 2, 283–290. doi:10.1038/clpt.2010.311</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2010.311</identifier><identifier>PMID: 21191378</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacokinetics ; Antibodies, Monoclonal - pharmacology ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; CD4 Antigens - immunology ; Histocompatibility Antigens Class I - metabolism ; Humans ; Medical sciences ; Models, Biological ; Papio ; Pharmacology. Drug treatments ; Receptors, Fc - metabolism ; Translational Medical Research</subject><ispartof>Clinical pharmacology and therapeutics, 2011-02, Vol.89 (2), p.283-290</ispartof><rights>2011 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4641-7010c9d461e3a8910e5783d08d562b3d0cacacc9710ecd527823d1606a4adae43</citedby><cites>FETCH-LOGICAL-c4641-7010c9d461e3a8910e5783d08d562b3d0cacacc9710ecd527823d1606a4adae43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2010.311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2010.311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27928,27929,45578,45579</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23932108$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21191378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Y</creatorcontrib><creatorcontrib>Scheerens, H</creatorcontrib><creatorcontrib>Davis, JC</creatorcontrib><creatorcontrib>Deng, R</creatorcontrib><creatorcontrib>Fischer, SK</creatorcontrib><creatorcontrib>Woods, C</creatorcontrib><creatorcontrib>Fielder, PJ</creatorcontrib><creatorcontrib>Stefanich, EG</creatorcontrib><title>Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (PK/PD) data in baboons suggest that the increased binding to FcRn reduces the nonspecific elimination rate (Kel) of MTRX1011A by ~50% but does not affect its PK–PD relationship. The human PK/PD data of MTRX1011A from a phase I study in patients with rheumatoid arthritis (RA) were compared with those previously reported for TRX1, its predecessor antibody, using population PK–PD modeling. The results suggest a comparable PK–PD relationship and no significant difference between the Kel values of the two antibodies. However, the results may have been confounded by the differences in the clinical populations in which the two antibodies were studied and the presence of preexisting immunoglobulin M (IgM) antibodies in the RA sera that recognize N434H in MTRX1011A. This study highlights the challenges in translating from animal studies to human application the effects of FcRn‐directed mutations on the PK of monoclonal antibodies.
Clinical Pharmacology & Therapeutics (2011) 89 2, 283–290. doi:10.1038/clpt.2010.311</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>CD4 Antigens - immunology</subject><subject>Histocompatibility Antigens Class I - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Papio</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Fc - metabolism</subject><subject>Translational Medical Research</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtvEzEUhS1ERdPCki0yi6qrKX7My8tqIFApFREEttaN7QiDxw72jKr8Bv40HiYNu8oL-5773WP7IPSakhtKePtOuf1ww0guOaXP0IJWnBV1xavnaEEIEYVgvD5HFyn9zGUp2vYFOmeUCsqbdoH-bCL45GCwwYPD6x8Qe1Dhl_VmsCph8Pok6oOHfhLDLut4qb744jtEC37At36wRfe-xPfBB-X-mU3aNk_hZQw9XkejnPVW5c590MbhIUzWyeA7_HUY9eElOtuBS-bVcb9E35YfNt2nYvX54113uypUWZe0aPJnldBlTQ2HVlBiqqblmrS6qtk2HxTkpUSTO0pXrGkZ17QmNZSgwZT8El3PvvsYfo8mDbK3SRnnwJswJtmWtSCsIVUmi5lUMaQUzU7uo-0hHiQlcopfTvHLKX6Z48_8m6PzuO2NPtGPeWfg6ghAykHscvjKpv8cF5xRMnFi5h6sM4enb5XdetOt1pupnh_xdp71MIzRnIanoUfmL-FSq2A</recordid><startdate>201102</startdate><enddate>201102</enddate><creator>Zheng, Y</creator><creator>Scheerens, H</creator><creator>Davis, JC</creator><creator>Deng, R</creator><creator>Fischer, SK</creator><creator>Woods, C</creator><creator>Fielder, PJ</creator><creator>Stefanich, EG</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201102</creationdate><title>Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study</title><author>Zheng, Y ; Scheerens, H ; Davis, JC ; Deng, R ; Fischer, SK ; Woods, C ; Fielder, PJ ; Stefanich, EG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4641-7010c9d461e3a8910e5783d08d562b3d0cacacc9710ecd527823d1606a4adae43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>CD4 Antigens - immunology</topic><topic>Histocompatibility Antigens Class I - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Papio</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Fc - metabolism</topic><topic>Translational Medical Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Y</creatorcontrib><creatorcontrib>Scheerens, H</creatorcontrib><creatorcontrib>Davis, JC</creatorcontrib><creatorcontrib>Deng, R</creatorcontrib><creatorcontrib>Fischer, SK</creatorcontrib><creatorcontrib>Woods, C</creatorcontrib><creatorcontrib>Fielder, PJ</creatorcontrib><creatorcontrib>Stefanich, EG</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Y</au><au>Scheerens, H</au><au>Davis, JC</au><au>Deng, R</au><au>Fischer, SK</au><au>Woods, C</au><au>Fielder, PJ</au><au>Stefanich, EG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2011-02</date><risdate>2011</risdate><volume>89</volume><issue>2</issue><spage>283</spage><epage>290</epage><pages>283-290</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>MTRX1011A is a humanized anti‐CD4 antibody with an amino acid substitution (N434H) to improve its binding to the neonatal Fc receptor (FcRn). Pharmacokinetic/pharmacodynamic (PK/PD) data in baboons suggest that the increased binding to FcRn reduces the nonspecific elimination rate (Kel) of MTRX1011A by ~50% but does not affect its PK–PD relationship. The human PK/PD data of MTRX1011A from a phase I study in patients with rheumatoid arthritis (RA) were compared with those previously reported for TRX1, its predecessor antibody, using population PK–PD modeling. The results suggest a comparable PK–PD relationship and no significant difference between the Kel values of the two antibodies. However, the results may have been confounded by the differences in the clinical populations in which the two antibodies were studied and the presence of preexisting immunoglobulin M (IgM) antibodies in the RA sera that recognize N434H in MTRX1011A. This study highlights the challenges in translating from animal studies to human application the effects of FcRn‐directed mutations on the PK of monoclonal antibodies.
Clinical Pharmacology & Therapeutics (2011) 89 2, 283–290. doi:10.1038/clpt.2010.311</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>21191378</pmid><doi>10.1038/clpt.2010.311</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2011-02, Vol.89 (2), p.283-290 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_846902705 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology Arthritis, Rheumatoid - drug therapy Biological and medical sciences CD4 Antigens - immunology Histocompatibility Antigens Class I - metabolism Humans Medical sciences Models, Biological Papio Pharmacology. Drug treatments Receptors, Fc - metabolism Translational Medical Research |
| title | Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T15%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translational%20Pharmacokinetics%20and%20Pharmacodynamics%20of%20an%20FcRn-Variant%20Anti-CD4%20Monoclonal%20Antibody%20From%20Preclinical%20Model%20to%20Phase%20I%20Study&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Zheng,%20Y&rft.date=2011-02&rft.volume=89&rft.issue=2&rft.spage=283&rft.epage=290&rft.pages=283-290&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2010.311&rft_dat=%3Cproquest_cross%3E846902705%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=846902705&rft_id=info:pmid/21191378&rfr_iscdi=true |